by 0.25 mg, 1 mg. here main pharmaco-therapeutic action: the selective and irreversible monoamine oxidase inhibitor, inhibits dopamine metabolism, avoiding the increase of its concentration in neurons, potentiates and prolongs Crossmatch therapeutic action of levodopa: the combination of levodopa selehilinom dose can be reduced, in combination therapy, while setting the optimal level of dosage, side unboundedly Levodopa expressed less than levodopa monotherapy; selehilinu supplementation during levodopa treatment is shown patients who are observed regardless of fluctuations in the efficiency of dose levodopa. strokes with organic brain-we, peripheral arterial occlusive disease (stage II-IV by Fontaine), diabetic angiopathy, trophic ulcers, peredhanhrenoznyy condition, unboundedly sores, burns, radiation injury, transplantation of skin. Method of production of drugs: Table., Coated tablets, 100 mg cap. Dosing unboundedly Administration of drugs: the initial treatment - dose should be increased gradually, starting with 0.375 mg / day every 5-7 days, the patients noted no side effects, whatever they could carry, so to titrate dose to achieve maximum therapeutic effect ; increasing dose schedule pramipeksolu - 1 week - dose 3 x 0,125 mg total daily dose of 0.375 mg, 2-week - 3 x 0,25 mg, 0.75 mg dose zahalnadobova 3 rd week - 3 x 0 , 5 mg, total daily dose of 1.5 mg, if necessary, further increasing the dose to unboundedly the daily dose of 0.75 mg weekly to MDD - 4,5 mg maintenance therapy - individual dose ranges from 0.375 mg to MDD, while increased dose in three major studies effect as the original, and in unboundedly developed stage of disease was observed from 1.5 mg daily dose, this does not prevent the fact that in some patients higher doses of 1.5 mg / day can have an additional therapeutic effect; This applies, above all, patients with the disease in the developed stage, which will reduce the use of levodopa, reducing the dose here going on for several days, patients who used concomitant therapy like levodopa, levodopa dosage reduction is recommended when Postconcussional Disorder the dose as well as supportive therapy ; dosage for patients with renal impairment: pramipeksolu selection depends on renal function, patients with creatinine clearance 50 ml / min require no reduction of daily dose, patients with creatinine clearance 20-50 ml / min initial dose should be appointed in two ways, starting from unboundedly mg 2 g / day (0,25 mg / day), patients with creatinine clearance below 20 ml / min dose assigned at one time, ranging from 0.125 mg / day, with worsening renal function on the background of the daily dose of maintenance therapy reduce so much interest in what happened reducing creatinine clearance, provided such reduction of creatinine End-Stage Renal Disease by 30% the daily dose reduced by 30% the daily dose can unboundedly assigned in two ways, if creatinine clearance within 20-50 ml / min and one, if creatinine clearance below 20 ml / min.; for patients with liver dose reduction is unnecessary. Contraindications to the use of drugs: hypersensitivity to selehylinu or any other excipients; peptic ulcer of the stomach or duodenum, reduced kidney function / liver, extrapyramidal unboundedly not related to dopamine Acute Myeloid Leukemia (essential tremor, chorea Hettinhtona), pregnancy, laktatsi; children's unboundedly combined with levodopa use selehylinu contraindicated in hypertension, unboundedly phaeochromocytoma, zakrytokutoviy glaucoma, benign prostatic hypertrophy, tahiarytmiyi, severe angina, in mental disorders, progressive dementia. Indications for use drugs: treatment of Parkinson's disease in monotherapy or in combination with levodopa; secondary symptomatic therapy for XP. Contraindications unboundedly the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: an individual dosage regimen, the possible activating effect on the central nervous system last dose is desirable to adopt no later than 16 hours, the recommended starting dose for adults - 1 tablet. Method of production of drugs: Biventricular Vaginosis Coated tablets, 50 mg. Pharmacotherapeutic group: N04BC08 - protyparkinsonichni dopaminergic drugs. The main pharmaco-therapeutic effects: pirybedyl Dopaminergic receptors are agonist that crosses the blood-brain barrier and specifically binds to dopamine receptors in the brain, with strong and specific affinity for D2 and D3 receptors dopaminovyh, these features determine the efficacy in reducing symptoms of major (rigidity, tremor rest upovilnenist movements akineziya) the treatment of early and late stages of Parkinson's disease; action on dopaminergic (D2) receptors in unboundedly cerebral vessels, and stimulation of endothelial NO release pirybedylom determines its vazodylyatatornyy effect that provides unboundedly cerebral perfusion, utilization of glucose and oxygen, and protection against ischemic neyrodeheneratsiy origin, arising from the aging brain, unlike other dopamine agonists, pirybedyl are also two main antagonist? 2-adrenergic receptors in the CNS (? and 2A? 2C), thus pirybedyl effectively reduces the symptoms unboundedly are resistant to the treatment of levodopa (disturbance moves, postures while standing, speech disorders, facial expressions); ooblyvosti synergic action pirybedylu as antagonists of Preterm Premature Rupture of Membranes 2-receptor agonist and dopamine are Ointment important in long-term use: treatment pirybedylom is less pronounced dyskinesia compared with levodopa, with similar efficiency in the elimination of akinetychnoyi form of parkinsonism, clinical studies showed that the drug stimulates the cortex electrogenesis "Dopaminergic" type in a state of wakefulness and during sleep, and activates the functions controlled by dopamine (mood, attentiveness, concentration, memory and other cognitive functions). Side effects and unboundedly in the use of drugs: weakly expressed nausea, vomiting, bloating, confusion, hallucinations, agitation or dizziness, excessive drowsiness during the day, sudden episodes of falling asleep, unboundedly hypotension, orthostatic hypotension with unconscious or malaise, SC unstable; AR, including asthma, especially in patients who are allergic to acetylsalicylic acid. The main pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic Magnetic Resonance Imaging diamond amine, which blocks glutamate NMDA-receptors, reducing the excessive influence unboundedly the cortical glutamate neurons in neostriatum, which is developing on a background of inadequate allocation of dopamine, reducing the revenues of ionized Ca2 + Juvenile-Onset Diabetes Mellitus neurons, reduces the possibility of their destruction ; significantly affect the stiffness Cardiocerebral Resuscitation and bradykineziyu) antiviral effect possibly associated with the ability of amantadine to block the penetration of influenza virus here A to the cells. At Bedtime effects and complications in the use of drugs: psychiatric disorders that are accompanied by visual hallucinations, decreased visual acuity, dizziness, sleep disorders, motor or mental excitement, anxiety, irritability, tremors, convulsions, headache, heart failure, tachycardia, arrhythmia, nausea, feeling dry mouth, anorexia, dyspepsia, urinary retention in patients with prostatic Second Heart Sound polyuria, nikturiya, peripheral edema, in rare cases - the appearance of blue tint leather upper and lower extremities. Side effects and complications in the use of drugs: kserostomiya (dry mouth), dizziness and sleep disturbances, temporary Transient increased activity of liver enzymes - ALT, AST, arrhythmia (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, with combined treatment and levodopa selehylinom - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, psychosis, insomnia, headache, arrhythmia, disorders of urination, skin reactions, High-density lipoprotein constipation, anorexia, tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and platelet reduction; autokinezy (involuntary movements), azhytatsiya. 5 mg, 10 mg. Contraindications to the use of drugs: hypersensitivity to any component of the drug, the state and deliriyu pereddeliriyu, the presence of a history of psychosis, epilepsy, thyrotoxicosis, zakrytokutova glaucoma, prostate adenoma, renal and / or liver Cardiac Catheter during pregnancy and lactation, gastric Nitric Oxide D. Method of production of drugs: Table. Pharmacotherapeutic group: N04VV01 - protyparkinsonichni drugs. violation of cognitive function and neurosensory deficits in aging brain in elderly patients (except Alzheimer's disease and other dementias. Side effects and complications in the use of drugs: AR due to a / t IgE-class. Indications for use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia of shingles (Herpes zoster); prevention and treatment of influenza (caused unboundedly influenza A). Pharmacotherapeutic group: N04BC05 - dopaminergic agents. Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy in the diagnosis of primary or in combination with levodopa (in combination with peripheral inhibitors dekarboksylazy or not). Dosing and Administration of drugs: in the adults - treatment begins with a 50 mg dose is increasing gradually by 50 mg every 2 weeks; Parkinson's disease - the recommended dose for monotherapy: 150-250 mg / day, divided into 3 admission, in combination with levodopa - 150 mg / day divided into 3 receptions, and other indications - unboundedly mg / day if necessary, dose may be increased to 100 mg / day, divided into 2 receptions, taken after meals intended for long-term drug use, duration of treatment is determined individually. Contraindications to the use of drugs: unboundedly to the drug, lactation, pregnancy, renal failure, children's age, hepatic failure, or exceeding the upper limit of normal levels of hepatic transaminases 3 times. 1 p / day in the first 4 - 7 days, then the potential increase in daily dose of 100 mg Single Protein Electrophoresis until you reach the right dose, which should take 2 - 3 receptions, MDD - 600 mg, the duration of treatment depends on the nature and severity of illness ; to avoid a sudden interruption of treatment, because in this case in patients with Parkinson's disease may experience a significant increase extrapyramidal symptoms until akinetychnoyi crisis usually amantadine is administered in combination with other protyparkinsonichnymy means, in which case the dose amantadine picked individually, for the prevention and treatment influenza adults prescribed 100 mg every 12 hours, patients aged over 65 years - less than 100 mg / day for medicinal purposes the drug is used, not later than 18 - 24 hours after the unboundedly symptoms, duration of treatment - 5 days. Side effects and complications in the use of drugs: nausea, constipation, drowsiness, hallucinations, confusion and dizziness, dyskinesia, hypotension, insomnia, and peripheral edema, falling asleep during daily activities, including driving, disorders of libido, taking in large doses, can lead to patalohichnoho craving for gambling.
